Mendus

.Hero-module--bg-image--629a6:before { opacity: 1; background-image: url('/static/64ff3c5dc09358fb1f6e6ee5f4a8dcf4/e65ba/Mendus_woman-with-surfboard_darker-min-compress.jpg'); }

Changing the course of cancer treatment
We harness the power of the body's immune system to keep tumor cells in check without harming health or quality of life.

<picture><source type="image/webp" srcSet="/static/f6777646b01027295d9a7ee75dea7c96/dbb21/disarming-cancer-threat.webp 151w,/static/f6777646b01027295d9a7ee75dea7c96/8cdf4/disarming-cancer-threat.webp 302w,/static/f6777646b01027295d9a7ee75dea7c96/39272/disarming-cancer-threat.webp 603w" sizes="(min-width: 603px) 603px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 603px) 603px, 100vw" decoding="async" loading="lazy" src="/static/f6777646b01027295d9a7ee75dea7c96/d2caf/disarming-cancer-threat.jpg" srcSet="/static/f6777646b01027295d9a7ee75dea7c96/bedb7/disarming-cancer-threat.jpg 151w,/static/f6777646b01027295d9a7ee75dea7c96/8f82e/disarming-cancer-threat.jpg 302w,/static/f6777646b01027295d9a7ee75dea7c96/d2caf/disarming-cancer-threat.jpg 603w" alt="&lt;p&gt;Middle aged man running in a field of grass, surrounded by mountains.&lt;/p&gt;
"/></picture>
Gaining the 
upper handToday, tumor recurrence causes the vast majority of cancer-related deaths. We want to change this by designing new therapeutic options that tip the balance in favor of the immune system.
What we do

<picture><source type="image/webp" srcSet="/static/aafedabe406814250bbca33ccd38dca0/5b094/ways-to-make-dif.webp 225w,/static/aafedabe406814250bbca33ccd38dca0/ecbb3/ways-to-make-dif.webp 450w,/static/aafedabe406814250bbca33ccd38dca0/10d3d/ways-to-make-dif.webp 900w" sizes="(min-width: 900px) 900px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 900px) 900px, 100vw" decoding="async" loading="lazy" src="/static/aafedabe406814250bbca33ccd38dca0/a3b1e/ways-to-make-dif.jpg" srcSet="/static/aafedabe406814250bbca33ccd38dca0/51892/ways-to-make-dif.jpg 225w,/static/aafedabe406814250bbca33ccd38dca0/ea40c/ways-to-make-dif.jpg 450w,/static/aafedabe406814250bbca33ccd38dca0/a3b1e/ways-to-make-dif.jpg 900w" alt=""/></picture>
New ways to make a differenceWe dare to shine the light of science down new and unexplored paths to improve the course of cancer treatment.
About us

Latest newsAll news
25 May 2023Latest
Mendus to participate in upcoming conferences in June 2023
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and...
Learn more
12 May 2023
Report from the Annual General Meeting of Mendus AB (publ) on 12 May 2023
At the annual general meeting (the “AGM”) of Mendus AB (publ), reg. no. 556629-1786, (the “Company”), on 12 May 2023 the AGM adopted, inter alia, the following resolutions. For more detailed...
Learn more
12 May 2023
Mendus AB (publ) Interim Report January – March 2023
In the first quarter of 2023, Mendus continued on the path set out by the key progress realized at the end of 2022. The Phase 2 monotherapy proof-of-concept data from the ADVANCE II trial presented...
Learn more
11 May 2023
Mendus announces two upcoming presentations at the EHA2023 Hybrid Congress
MENDUS TO PRESENT UPDATES ON IMMUNOMONITORING DATA FROM ADVANCE II TRIAL AND PROGRESS ON THE DEVELOPMENT OF ITS NK CELL THERAPY PROGRAM  Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company...
Learn more
28 April 2023
Change in number of shares and votes in Mendus AB (publ)
During April, the number of shares and votes in Mendus AB (publ) has changed as a result of 1,383,106 new shares being issued to Negma Group upon conversion of convertible bonds.  The issue of shares...
Learn more
27 April 2023
Mendus to participate in upcoming conferences in May 2023
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and...
Learn more
26 April 2023
Mendus announces two upcoming presentations at the 2023 CIMT Annual Meeting
UPDATED CLINICAL DATA FROM ADVANCE II TRIAL TO BE SHARED IN AN ORAL PRESENTATION AND POSTER ON NEXT-GENERATION IMMUNE PRIMER PROGRAM  Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company...
Learn more

For investors
Invest in future cancer careMendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
Investors
<picture><source type="image/webp" srcSet="/static/e3517795e1f9bcda1e6401e0dac3e35e/7bc26/124.webp 414w,/static/e3517795e1f9bcda1e6401e0dac3e35e/5e603/124.webp 828w,/static/e3517795e1f9bcda1e6401e0dac3e35e/af8c4/124.webp 1656w" sizes="(min-width: 1656px) 1656px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1656px) 1656px, 100vw" decoding="async" loading="lazy" src="/static/e3517795e1f9bcda1e6401e0dac3e35e/89e2a/124.jpg" srcSet="/static/e3517795e1f9bcda1e6401e0dac3e35e/1d336/124.jpg 414w,/static/e3517795e1f9bcda1e6401e0dac3e35e/8753d/124.jpg 828w,/static/e3517795e1f9bcda1e6401e0dac3e35e/89e2a/124.jpg 1656w" alt="&lt;p&gt;Close up of a middle aged woman dressed in a blazer, sitting down while looking at another person in the foreground.&lt;/p&gt;
"/></picture>
Latest presentation12 May 2023Corporate Presentation - May 2023
17 April 2023Replay Investor Webcast – April 2023
30 March 2023Innate Killer Summit 2023
13 December 2022Replay of ASH 2022 Webcast
30 November 2022Replay of Mendus' KOL Event
Financial calendar17 February 2023Publication of Year-end Report 2022
17 April 2023Publication of Annual Report 2022
12 May 2023Annual General Meeting
12 May 2023Publication of Q1 Report
29 August 2023Publication of Q2 Report
9 November 2023Publication of Q3 Report
14 February 2024Publication of Year-end Report 2023

EventsAll events
8 June 2023
Upcoming
EHA2023 Hybrid CongressMendus to present updates on immunomonitoring data from ADVANCE II trial and progress on the development of its NK cell therapy program.
Learn more
June 2023Upcoming
BIO International Convention
Erik Manting, CEO of Mendus, will attend the conference.
Learn more
June 2023Upcoming
Redeye Growth Day
Mendus CEO Erik Manting will participate in a live Q&A session on June 1st.
Learn more
May 2023Previous
CCBIO’s 11th Annual Symposium
Mendus will present immunomonitoring and research data supporting the mode of action of its lead program vididencel.
Learn more

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89.gbi--1792894973-ja32foyRxBRHTmJvCSuGjh:before { opacity: 1; background-image: url('/static/db5cac225ec6b40b3e48015942da980e/d3468/home-section-fullwidth.jpg'); }

A life-changing careerAt Mendus, we share a strong commitment to improve the lives of people with cancer. And we do it as a team who values honesty and togetherness. Join us and help change cancer treatment at its core.
Careers

Changing the course of cancer treatment

Gaining the upper hand

New ways to make a difference

Latest news

Mendus to participate in upcoming conferences in June 2023

Report from the Annual General Meeting of Mendus AB (publ) on 12 May 2023

Mendus AB (publ) Interim Report January – March 2023

Mendus announces two upcoming presentations at the EHA2023 Hybrid Congress

Change in number of shares and votes in Mendus AB (publ)

Mendus to participate in upcoming conferences in May 2023

Mendus announces two upcoming presentations at the 2023 CIMT Annual Meeting

For investors

Invest in future cancer care

Latest presentation

Financial calendar

Events

EHA2023 Hybrid Congress

BIO International Convention

Redeye Growth Day

CCBIO’s 11th Annual Symposium

A life-changing career

Keep up to date

Gaining the
upper hand